Annexon, Inc. Stock Price, News & Analysis

Annexon (Nasdaq: ANNX) priced an underwritten public offering to raise approximately $75.0 million in gross proceeds.

The offering includes 25,096,153 shares of common stock at $2.60 per share and 3,750,000 pre-funded warrants at $2.599 each, and is expected to close on November 14, 2025, subject to customary conditions. Underwriters have a 30-day option to buy up to 4,326,922 additional shares.

Annexon (NASDAQ: ANNX) announced on November 12, 2025 that it has commenced an underwritten public offering of $75.0 million of common stock or pre-funded warrants, with a 30-day underwriter option for up to an additional $11.25 million. The proposed offering is being made from a Form S-3 shelf registration declared effective on April 1, 2024 and is subject to market and other conditions.

Goldman Sachs, TD Cowen and Wells Fargo Securities are acting as joint book-running managers. Final offering terms will be disclosed in a prospectus supplement to be filed with the SEC; there is no assurance the offering will be completed or on the proposed size or terms.

Annexon (Nasdaq: ANNX) reported Q3 2025 results and portfolio progress, highlighting late-stage programs in Guillain-Barré syndrome (GBS), geographic atrophy (GA), and an oral C1s program. Cash and short-term investments were $188.7M as of Sept 30, 2025, with runway into late Q1 2027. Key near-term milestones: MAA filing for tanruprubart (ANX005) in Jan 2026, topline Phase 3 ARCHER II data for vonaprument (ANX007) expected in H2 2026, and ANX1502 CAD proof-of-concept study completion in 2026. Q3 R&D expenses rose to $49.7M and net loss widened to $54.9M (Q3 2025).

Annexon Biosciences (NASDAQ:ANNX), a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases, has announced its participation in two major investor conferences in September 2025.

The company's President & CEO Douglas Love will engage in fireside chats at the Wells Fargo Healthcare Conference on September 3 at 3:00 p.m. ET in Boston, and the Cantor Global Healthcare Conference on September 4 at 8:00 a.m. ET in New York. Both presentations will be available via webcast on the company's website for 30 days after the events.

Annexon (Nasdaq: ANNX), a biopharmaceutical company focused on classical complement-mediated neuroinflammatory diseases, has granted stock options to a new non-executive employee. The inducement grant was approved on August 11, 2025, under the company's 2022 Employment Inducement Award Plan and Nasdaq Listing Rule 5635(c)(4).

The grant consists of options to purchase 60,000 shares of Annexon common stock at an exercise price of $2.44 per share. The options have a ten-year term and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years.

Annexon (NASDAQ:ANNX) reported Q2 2025 financial results and pipeline updates for its complement-mediated disease therapies. The company ended Q2 with $227 million in cash, supporting operations into Q4 2026. Key highlights include:

For tanruprubart (GBS treatment): MAA submission in Europe planned for Q1 2026, with ongoing FDA discussions. About 90% of treated patients showed week 1 improvement, with twice as many achieving normal health vs placebo at week 26.

For vonaprument (dry AMD treatment): Completed enrollment of 659 patients in Phase 3 ARCHER II trial, with topline data expected in H2 2026. Selected for EMA's PRIME Product Development pilot.

Q2 2025 financials show R&D expenses of $44.2M (vs $25.0M in Q2 2024) and net loss of $49.2M ($0.34 per share) compared to $29.6M ($0.23 per share) in Q2 2024.

[ "Strong cash position of $227M supporting operations through Q4 2026", "90% of tanruprubart-treated GBS patients showed week 1 improvement, with 2x more achieving normal health vs placebo", "Accelerated enrollment completion of 659 patients in Phase 3 ARCHER II trial for vonaprument", "Selection for EMA PRIME Product Development Coordinator pilot program", "ANX1502 oral C1s inhibitor exceeded target concentration in fasted patients" ]

Annexon (NASDAQ:ANNX) announced that its drug candidate vonaprument has been selected by the European Medicines Agency (EMA) for the Product Development Coordinator (PDC) pilot program. Vonaprument, designed to treat dry age-related macular degeneration (AMD) with geographic atrophy (GA), is among approximately 20 PRIME development programs chosen for this initiative.

The drug has received PRIME designation in Europe and Fast Track Designation from the FDA. It is currently being evaluated in the ARCHER II Phase 3 trial, with topline data expected in H2 2026. Notably, vonaprument is the only investigational therapy in GA showing significant vision preservation in both best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA).

Annexon (NASDAQ:ANNX) has completed enrollment for its pivotal Phase 3 ARCHER II trial of vonaprument for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The trial exceeded its target of 630 participants, demonstrating strong demand for vision-preserving therapy. Topline data is expected in H2 2026.

Vonaprument, a first-in-kind non-pegylated antigen-binding fragment, showed promising results in Phase 2 trials as the only investigational therapy demonstrating significant vision preservation through best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA). The drug has received PRIME designation in Europe and Fast Track designation in the U.S., positioning it to potentially become the first treatment approved in both regions for dry AMD with GA based on visual acuity protection.

Annexon (NASDAQ: ANNX) has appointed Dr. Lloyd Clark as SVP of ophthalmology strategy and innovation to advance their ANX007 program for dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA). Dr. Clark brings 25 years of experience as a retina specialist and has been principal investigator in over 70 clinical trials. ANX007, a non-pegylated Fab designed to block C1q locally in the eye, is the only investigational therapy shown to significantly preserve vision and central retinal photoreceptors in GA patients. The company's Phase 3 ARCHER II trial is expected to complete enrollment in Q3 2025, with topline data anticipated in H2 2026. Dry AMD with GA affects over 8 million patients globally with no approved therapies targeting vision preservation. Dr. Clark's appointment strengthens Annexon's expertise as they advance towards potential global registration of ANX007.